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ABSTRACT
THE RELATIONSHIP BETWEEN PRO-STRESS AND
ANTI-STRESS RECEPTORS IN THE STRESS-LEARNING
BRAIN REGIONS OF FEMALE MICE
Nathan Popp
Director: Cliff H. Summers, Nolop Distinguished Professor

Human men and women react to stress in different ways, both biologically and
psychologically (Verma et al., 2011). Orexins (or hypocretins) are neuropeptides involved in
eliciting a stress response and have been shown to have opposing actions via two different
receptors. Activation of the Orx1 receptor promotes stress, while activation of the Orx2 receptor
relieves stress (Staton et al., 2018). Using the Stress Alternatives Model (a four-day paradigm in
which small female mice are in an open arena with a larger aggressor mouse), distinct
phenotypic behaviors can be observed after the second day: anxiety-prone and stress-resilient.
After the second day, animals will commit to one specific phenotype. Using an Orx2 receptor
antagonist (MK-1064) and an α2 receptor antagonist (yohimbine), phenotypic behavior can
change even after mice have committed to a specific phenotype, as late as the third day. It has
been shown that the behavioral state of an animal, either anxiety-prone or stress-resilient, can
affect the number of neurons containing the orexin peptide (James et al., 2020). We hypothesize
that the stress-resilient mice will show more Orx2 containing neurons in the basolateral amygdala
(BLA). We examined the number of cells in the BLA containing Orx2 receptors and determined
the peptide cell markers that define this receptor action. The neuropeptides cholecystokinin
(CCK) and somatostatin (SOM) were found on a minority of neuronal cells in the BLA. CCK
can either be glutamatergic or GABAergic, while SOM is one type of GABAergic cell in the

BLA. The inhibitory effects of GABAergic cells reduce stress, while excitatory glutamatergic
cells promote stress. Orx2 receptors are primarily found in GABAergic neurons that contain
CCK, and the number of cells with these receptors are not significantly different between males
and females, both before and after anxiogenic drug treatment. It is possible, however, that the
number of receptors on each cell increased in number.
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Introduction
Although the emotional states of fear, anxiety, and depression have adaptive value (Lovick
and Zangrossi 2021), these stress-dependent conditions are also associated with significant
dysfunction in human populations. Men and women react to stress in very different ways, both
biologically and psychologically (Verma et al., 2011). Women can be up to three times as likely
to be diagnosed with depression than men (Wang et al., 2017); In contrast, men commit suicide
almost four times as often as women (Miron et al., 2019). These psychological disorders can be
considered “stress disorders” because their etiology corresponds in time and magnitude to the
expression of stress-related hormones, neuromodulators, and the activity of specific stress-related
neurocircuitries. Stress disorders are classified as either depressive or anxious. Examples of
depressive stress disorders include depression, post-traumatic stress disorder (PTSD), and
dysthymia. Anxious stress disorders include obsessive compulsive disorder (OCD), eating
disorders such as bulimia and anorexia, general anxiety disorder, insomnia, phobias, and panic
disorder (Bandelow & Michaelis, 2015). Over 46 million Americans are affected by depressive
stress disorders (Daly et al., 2021), and up to 112 million Americans are affected by anxious
stress disorders (Bandelow & Michaelis, 2015).
Nervous, endocrine, and immune systems work together in an integrated way to produce
what is collectively called a stress response (Yaribeygi et al., 2017). Any stimulus that invokes a
physiological response is known as a stressor, which may alter homeostasis and modify the
course of diseases (Yaribeygi et al., 2017). Stress responses are highly regulated, and very
similar across a variety of species; a very highly conserved evolutionary response (Bergstrom &
Mecham, 2016). Activating the stress response causes a change in behavioral and physiological
processes that aim to help an individual improve their chances of survival in the face of danger,
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but when chronically activated, can produce maladaptive behaviors associated with heightened
anxiety and/or depressive behavior. The hypothalamus-pituitary-adrenal (HPA) axis (Smith &
Vale, 2006; Stephens & Wand, 2012) includes the paraventricular nucleus of the hypothalamus,
anterior lobe of the pituitary gland, the adrenal gland, and the hormones that they secret. The
HPA axis is stimulated by the hormones epinephrine and norepinephrine, released by the
sympathetic nervous system after encountering a stressor. The hypothalamus responds by
releasing corticotropin-releasing hormone (CRH), which stimulates the pituitary gland to release
adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to release
glucocorticoids, such as the hormone cortisol (Nicolaides et al., 2020). Cortisol acts to help
increase cardiac output and increases circulating levels of glucose in the bloodstream, while also
decreasing reproductive activity.
However, these are not the only hormones involved in a stress response. Corticotropinreleasing hormone is known to interact with neuropeptides called orexins or hypocretins
(Borgland et al., 2010). Orexins play a vital role in responding to stress. Made in the
hypothalamus, the orexins are responsible for regulating behaviors such as wakefulness, appetite,
thirst, and arousal. There are two main types of orexins: orexin A (OrxA) and orexin B (OrxB).
Similarly, there are two types of orexin receptors: Orx1 and Orx2 (Heinonen et al., 2008). These
receptors are G-protein coupled receptors (Han et al., 2019). It has been shown that the Orx1
receptor has a much higher affinity for OrxA than OrxB, while the Orx2 receptor has similar
affinity for both neuropeptides (Ebrahim et al., 2002). Most of the orexin made in the
hypothalamus is made in a region called the dorsolateral hypothalamus, with orexin being
projected to certain brain regions such as the amygdala, locus coeruleus, dorsal raphe nucleus,
basal forebrain, and spinal cord (Ebrahim et al., 2002). One region of interest to our group was
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the BLA. We have shown that the orexin receptors in the BLA work in an opposing fashion; in
other words, activation of the Orx1 receptor promotes stress, while activation of the Orx2 receptor
relieves stress (Staton et al., 2018).
The goal of our experiments is to improve the understanding of the actions of the orexin
receptors. In the BLA, opposing Orx1 and Orx2 actions come about because of the localization of
each receptor type to specific kinds of cells (Yaeger et al., 2020 and 2022). Importantly, the
number of cells in the hypothalamus containing orexin peptides can change based on behavioral
state of the animals (James et al., 2019). We extend this finding, by asking if the number of cells
containing orexin receptors in the BLA can also change based on behavioral phenotype,
specifically the anxiety-prone Stay animals as compared with the stress-resilient Escape animals.
Only a small number of excitatory glutamatergic (Glu) pyramidal neurons in the BLA express
Orx1 receptors, but this limited expression in the pyramidal pro-stress circuitry is enough to
promote anxious and depressive behavior (Yaeger 2022). Conversely, Orx2 receptors are found
in only a few inhibitory GABAergic neurons, but which are potent enough to limit pro-stress
actions. To conduct this hypothesis, we are using mice and testing their behavioral responses to
stressful situations and later examining their BLA for orexin receptors. In female mice, we are
specifically looking at Orx2 expression in the BLA as well as alpha 1A (α1A) and alpha 2A (α2A)
adrenergic receptors. These α receptors respond to norepinephrine, a common stress hormone
and transmitter. While Orx2 receptors reduce anxious and depressive behavior when delivered
into the cerebral ventricles (Staton et al., 2018), adrenergic receptors, including α1A and α2A,
stimulate anxiety (Schramm et al., 2001). Their actions in the BLA depend on localization to
specific microcircuits. This study is designed to examine gene expression for these receptors, and
to determine the relative level of expression, and in which neurons that expression occurs. A
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specific interest to our group involves measuring α receptors in the same brain region and
examining both receptors to see if they differ in males and females, since it has been shown that
females have higher orexin system expression than males (Grafe et al., 2019).
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Materials and Methods
Animals
For this experiment, we used male and female C57BL/N6 mice, aged 6-12 weeks. They
were housed briefly in a group setting (4-5 mice per cage for 5 days) before being individually
housed. Lighting was set to a 12:12 light-dark cycle with lights turning off at 6 p.m., with the
temperature maintained at 22oC, and water and food ad libitum. Singly housed male mice were
used as aggressor mice in the behavioral paradigms. C57BL/N6 test mice were handled daily for
7 days prior to behavioral trials. Procedures were performed in ways that minimized suffering
and the use of animals and were in accordance with the NIH's Guide for the Care and Use of
Laboratory Animals and approved by the IACUC of USD.
Drugs
An Orx2 receptor (Orx2R) antagonist (MK-1064; IC50 = 18 nM for Orx2R), an α2 receptor
antagonist (yohimbine), and vehicle (1:3, Saline to DMSO ratio) were delivered in a similar
fashion on Day 3 via a subcutaneous (sc) injection. A dose response was performed on females
as we were unsure which dose of MK-1064 to use. Our high dose (1 µmol) was chosen to be
under that necessary to induce sleep in mice (Roecker et al., 2014). A dose of 5mg/kg was used
for our yohimbine control group for pharmacological studies in females, which blocked escape in
male mice (Smith et al., 2016).
Behavioral Paradigms
The primary behavioral paradigm used in these studies utilized the Stress Alternatives Model
(SAM). The SAM utilizes a 4-day experimental plan, with 5mins/day, that starts with C57BL/N6
test animals being introduced to an opaque cylinder in the center of an oval-shaped, open field
arena (Figure 1). An aggressor male mouse (CD1) roams the arena outside of the cylinder. After
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a 30 second period, a tone is played for 5 seconds. This tone represents the conditioned stimulus
(CS). A 10 second trace period follows the tone, which is succeeded by lifting of the cylinder
and allowing the aggressive mouse to attack the test animal. The attacks are an unconditioned
stimulus (US). Most importantly, no test mouse encounters the same aggressor mouse twice
throughout the paradigm. Located on opposite apical ends of the oval-shaped arena are two
escape routes, allowing the smaller test mouse to escape aggressive behaviors from the
aggressor. In male mice, the end of the second day marks the commitment to one of two stable
behavioral phenotypes: Stay and Escape. This commitment allows for pharmacological
intervention on Day 3, which may reverse the chosen phenotype. Anxiolytic drugs initiate escape
behaviors in Stay mice, whereas anxiogenic drugs delay escape time and promote Stay behavior
(Yaeger et al., 2022). A purpose of the following studies was to investigate how female behavior
in the SAM differs from that in males.
To explore female behavior with our developed method, we exposed female C57BL/6N mice
to several unique paradigms. A group of female mice were presented with the standard 4-Day
SAM paradigm. A separate experimental design utilized the standard 4-Day SAM paradigm with
subcutaneous (sc) drug administration on Day 3. At the end, mice were briefly anesthetized with
5% isoflurane for 2 minutes and rapidly decapitated. Trunk blood was spun down for 5 minutes
in heparinized tubes and plasma was collected. Brains were extracted and flash frozen in cold
isopentane on dry ice.
All behavioral paradigm was performed during the animals’ awake period under red light.
Each behavioral trial was recorded using GoPro Hero 7 cameras, and videos were analyzed using
ANY-maze (version 6.0) software.
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In situ Hybridization - RNAscope
Sections of fresh frozen brains (coronal; 20 µm; relative to bregma AP -1.40 to -2.0) were
placed in cold (4°C) 10% formalin for 20 min and subsequently washed (2x for 1 min) in 1x
phosphate buffer solution (PBS), before dehydration with ethanol (50% x 1, 70% x 1, and 100%
x 3; 5 min each with the final ethanol being kept at -20°C overnight). The following day,
proteins were digested using a protease treatment and rinsed with dH2O. Brain sections were
incubated for two hours in RNAscope (Advanced Cell Diagnostics, Newark, CA) probes
(HCRTR2, Cat. No. 460881) in a hybridization oven (ACD HybEZ II oven) set to 40°C.
Fluorophores were linked to probes and signaling was enhanced through application of a series
of amplification buffers (RNAscope Fluorescent Multiplex Detection Reagents). Finally, tissue
was briefly stained with DAPI (20 sec) and coverslipped. Image acquisition was performed
fluorescence microscope (Nikon A1; 10x/0.30 Plan Fluor and 20x/0.75 Plan Apo VC Nikon
objectives) and NIS Elements software. The BLA was identified from images and analyzed
using QuPath 3.0 and ImageJ programs.
Statistics
Experimental design and analyses were based on a priori hypotheses. For changes
occurring across treatment/experimental groups we applied a one-way ANOVA. Non-stressed
cage controls were added for comparisons of in situ hybridization results, in which one-way
ANOVA was used. Assessments between two treatments/experimental conditions were
performed by Student’s two-tailed t-tests. Each mouse provided a single unit for analyses
involving a priori hypotheses. The five assumptions of parametric statistics were applied to the
data, transformed when necessary, compared to non-parametric analyses, and graphed in raw
form. Analyses for parametric and non-parametric statistics were used along with an
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examination for multiple comparisons applying the Holm-Sidak method. If the statistical
analyses match, as they do for the data herein, we report the parametric results without α
adjustment. Effects between groups for one-way analyses were examined with Student–
Newman–Keuls post hoc analyses (to minimize Type I error) and Duncan's Multiple Range Test
(to minimize Type II error).
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Results
Peptide and Orx2 receptor expression in the BLA
In the BLA, there are more CCK-positive (CCK+) cells than those that express Orx2
receptors (F2, 30 = 68.12, p < 0.001; Figure 2). Further, SOM-positive (SOM+) neurons make up
the smallest number of cells as there are fewer of them than those that are Orx2-positive (Orx2+)
and CCK+. There are distinct differences in the number of neurons that are CCK+, SOM+, or
Orx2+. Importantly, while there are broad differences in expression levels within these cell types,
there are no differences when comparing males to females for each cell type. Males and females
showed no significant difference in expression of Orx2+ cells (t = 1.657, p ≥ 0.05), SOM+ cells (t
= 0.233, p ≥ 0.05), or CCK+ cells (t = 1.796, p ≥ 0.05).
Somatostatin and Orx2 receptor expression in the BLA
Looking closer at only cells that express Orx2 receptors, we noticed that many cells were
CCK+ (~40%) and the minority of cells were SOM+ (>10%) (F1, 20 = 102.1, p ≤ 0.001; Figure 3).
Once again, there were no differences when comparing males to females (F1, 20 = 0.68, p ≤
0.419).
Treatment results on Orx2-positive cells in the BLA
After drug treatments, female mice administered yohimbine had a modest, yet not
significant, increase in Orx2-positive cells (Figure 4). Treatment with MK-1064 did not shift the
percentage of Orx2-expressing cells (F4, 19 = 2.109, p ≤ 0.120).
Treatment results on α2A-positive cells in the BLA
Female mice treated with yohimbine had an increase, though not significant, in α2Aexpressing cells (Figure 5). Treatment with the Orx2 receptor antagonist MK-1064 did not alter
the number of α2A-expressing cells (F4, 19 = 1.303, p ≤ 0.304).
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Treatment results on α1A-positive cells in the BLA
In the BLA, α1A expressing cells are increased after yohimbine treatment or MK-1064
treatment, but only in slow escape mice (Figure 6). Importantly, these shifts in α1A expression did
not reach statistical significance (F4, 19 = 1.621, p ≤ 0.210).
Treatment results on Orx2- and α2A-positive cells in the BLA
The number of Orx2-expressing cells that also express α2A is increased after yohimbine
treatment (Figure 7). However, this increase was not statistically significant. Female mice treated
with MK-1064 showed similar levels of cells expressing both Orx2 and α2A as vehicle treated
controls (F4, 19 = 1.772, p ≤ 0.176).
Treatment results on Orx2- and α1A-positive cells
Administration of yohimbine modestly, though not significantly, increased the percent of
cells expressing both Orx2 and α1A (Figure 8). Treatment of the Orx2 receptor antagonist MK1064 reduced the number of cells expressing Orx2 and α1A compared to vehicle treated controls.
This treatment group, however, did not differ from cage control mice (F4, 19 = 1.830, p ≤ 0.165)
(t8 = -2.567, p ≤ 0.05).
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Discussion
The organization of regulatory signaling in the BLA is beginning to be elucidated. Most
neurons in the BLA are glutamatergic, which comprise ~80% of the neuronal cells therein, while
the other neurons are primarily GABAergic. The GABA marker glutamate decarboxylase 1
(GAD1) is found in ~10% of neuronal cells. The Orx1 and Orx2 receptors are generally found in
different neuronal subtypes, with Orx1 mostly found on glutamatergic neurons, and Orx2 found
more often on GABAergic neurons (Yaeger et al., 2022). A major aim of this research was to
discover other neuronal markers for Orx2 containing cells, because not all GABAergic neurons
have Orx2, and not all Orx2 containing cells are GABAergic. Our experiment found that there
were no significant changes between males and females when looking at SOM, CCK, and Orx2
levels. While levels of SOM and CCK vary among cell types, levels of expression showed no
significant differences between males and females. We found that roughly 40% of neuronal cells
in the BLA contained CCK and Orx2, while only less than 10% contained SOM and Orx2. Orx2
is only found on ~12% of neuronal cells in the BLA. Furthermore, drug treatment with the α2
receptor antagonist yohimbine and Orx2 receptor antagonist MK-1064 showed some changes in
expression between α1A receptors, α2A receptors, and Orx2 receptors. However, these changes
were not significant. The only significant result was that treatment with MK-1064 reduced the
number of cells expressing both Orx2 and α1A compared to vehicle treated controls in fast
escaping females. This treatment group, however, did not differ from cage control mice.
Neurochemical Identity of BLA Neurons
The most common neuro-signaling molecule found in the BLA is the excitatory transmitter
glutamate; and the second most common is the inhibitory neurotransmitter GABA (Yeager et al.,
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2022). To understand the functional effects of the Orx2 receptors, we recognized that we must
locate the specific neurons in which those receptors are found. While we know that most Orx2
receptors are in GABAergic neurons, not all of these inhibitory neurons express this receptor. As
such, we identified other neuronal peptide markers, and found CCK and SOM are found on a
minority of neurons. A tiny minority of the neuronal cells in the BLA express SOM (<10%).
There are more CCK neurons present than Orx2 neurons, indicating that all CCK neurons cannot
express Orx2. Likewise, there are more Orx2 neurons than SOM neurons, showing that not all
Orx2 can be expressed on SOM neurons.
Colocalization of Orx2 Receptors with BLA Peptide Markers
We have found that many of the cells in the BLA that contain CCK also contain Orx2
receptors. This colocalization has shown that when one receptor is stimulated, the other is as
well. It has been shown that mice with reduced levels of CCK in the BLA show reduced anxiety
and less despair (Del Boca et al., 2012), in which orexin may play a role. It has been shown that
activation of Orx1 promotes an inhibition of GABA release from CCK-expressing interneurons,
which leads to an increased excitability to BLA projection neurons and influences a pro-stress
response (Yaeger et al., 2020). SOM is involved in regulating and secreting other peptides and
maintaining neuronal integrity, among other things (Kumar et al., 2020). Very few cells in the
BLA expressed SOM, as it is one type of GABA cell in the BLA. Our data show that very little
colocalization occurs between SOM+ cells and Orx+ cells. Studies have shown that the orexin
system works independently from the SOM system, which could be explained by the lack of
colocalization (Karasawa et al., 2014).
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Effects of Anxiogenic Drugs on Numbers of Cells expressing Receptors in the BLA
There were two drug treatments given, that promote anxiogenic (anxiety-causing) responses,
the α2-adrenoreceptor blocker yohimbine, and the Orx2 receptor antagonist MK-1064. Neither of
these treatments influenced the number of neurons that express Orx2, α1A, or α2A receptors in the
BLA. Previous results suggest that anxiolytic treatment (in contrast) does influence gene
expression of Orx2 receptors in the BLA via genetic knockdown, shifting behavioral expression
from stress-sensitive to stress-resilient. (Yaeger et al., 2022). It is important to note that
enhanced gene expression is not the same as increasing cell number expressing these peptides. It
is possible that the number of receptors on each cell increased in number; however, our results
show that there were no significant changes in cell numbers expressing these peptides.
When cell numbers containing both Orx2 and α1A receptors in the BLA are considered, there
was a significant difference in the number of cells containing both peptides compared to a
vehicle control in fast-escaping females when treated with MK-1064.
Comparisons between Male and Female Neuronal Numbers
Numerous studies have described differences in neurochemical signaling molecules between
males and females. For example, studies have shown that male mice have a higher level of
dopamine and serotonin than female mice, but females show a greater increase in serotonin and
dopamine release when stressed (Mitushima et al., 2006). Similarly, hormonal signaling is also
different for some systems between males and females. When stressed, females also show higher
levels of adrenocorticotropic hormone and corticosterone than males (Duchesne et al., 2009).
These studies suggest that stress signaling is specifically differentiated by sex. Related to our
work are stress related differences in orexinergic systems. Female mice were shown to have
higher orexin system expression compared to male mice (Grafe et al., 2019). Additionally, our

13

results show that there were no significant differences when comparing CCK, SOM and Orx2
receptor-containing cells in males and females. However, when added collectively, females had
fewer CCK plus SOM plus Orx2 receptor-containing cells in the BLA than males. Since these
cell types overlap somewhat, it is not clear if this represents any real reduction in BLA neurons.
It is possible that female BLA simply have fewer total neurons than males.
Comparisons of Fast and Slow Escaping Females
Female mice undergoing social aggressive interactions in the SAM react somewhat
differently than males. Males are divided into two behaviorally distinguishable phenotypes,
Escape and Stay. Females also have two unique behavioral phenotypes, even though all of them
Escape, and none Stay in the arena and continue to receive aggression. The two phenotypes are
distinguished by the amount of time it took to escape; females could either be fast-escaping or
slow-escaping. Fast-escaping females were females that escaped the arena in under 30 seconds
on day 3 or 4 of the paradigm, while slow-escaping females were females that escaped the arena
at a slower time than 30 seconds on day 3 or 4. Our findings did not show any difference
between fast-escaping and slow-escaping females, except when looking at cells containing both
Orx2 and α1A receptors in the BLA. When treated with MK-1064, fast-escaping females showed
a significant decrease in the number of cells containing both Orx2 and α1A receptors compared to
the vehicle control.
Conclusion
Stress-related behavior can be modulated in BLA stress pathways via Orx2 receptors
found primarily on GABAergic neuronal cells. The neurons in the BLA contain peptide signaling
molecules in addition to GABA and glutamate. The neuropeptide CCK can either be GABAergic
or glutamatergic, while the neuropeptide SOM is one type of GABA cell in the BLA. Both CCK
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and SOM were only found on a minority of cells in the BLA. While little differences were found
between males and females, differences in behavior were present, with males choosing to either
Escape or Stay in the arena and face social aggression, and females choosing to escape all the
time. After giving two anxiogenic drug treatments (yohimbine and MK-1064), there were no
significant changes in the number of neuronal cells expressing Orx2. Previous studies have
shown that the number of neuronal cells containing orexin peptides can change based on
behavioral phenotype (James et al., 2019). Because we did not see significant differences, it
would be important to look at a quantitative measure of mRNA for these peptides and receptors
to see if the total amount of gene expression is changing.
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Figure Legend
Figure 1
Stress Alternatives Model (SAM)

(Yaeger et al., 2022)
The Stress Alternatives Model (SAM) utilizes a 4-day experimental plan, with 5mins/day, that
starts with C57BL/N6 test animals being introduced to an opaque cylinder in the center of an ovalshaped, open field arena (I). An aggressor male mouse roams the arena outside of the cylinder.
After a 30 second period, a tone is played for 5 seconds (II). This tone represents the conditioned
stimulus (CS). A 10 second trace period follows the tone, which is succeeded by lifting of the
cylinder and allowing the aggressive mouse to attack the test animal (III). The attacks are an
unconditioned stimulus (US). Located on opposite apical ends of the oval-shaped arena are two
escape routes, allowing the smaller test mouse to escape aggressive behaviors from the aggressor.
In male mice, the end of the second day marks the commitment to one of two stable behavioral
phenotypes: Escape (IV) and Stay (V). This commitment allows for pharmacological intervention
on Day 3, which may reverse the chosen phenotype
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Figure 2
Peptide and Orx2 receptor expression in the BLA
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Fig 2. When looking at specific cell types, broad
differences are present between Orx2, CCK, and SOM.
Importantly, there are no significant differences when
comparing males and females of the same cell type (top).
Orx2 receptors, shown in red (bottom left). DAPI shown
in blue (bottom right).

17

Figure 3
Somatostatin and Orx2 receptor expression in the BLA
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Fig 3. CCK+ cells are more abundant in the BLA than SOM+ cells. There are
no differences when comparing males to females (top). DAPI shown in blue
(bottom left). CCK shown in green (bottom middle). SOM shown in pink
(bottom right). SOM colocalized with Orx2 (below left) and CCK colocalized
with Orx2 (below right).
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Figure 4
Treatment results on Orx2-positive cells in the BLA
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Fig 4. Neither treatment of yohimbine or MK-1064 statistically shifted the number of cells expressing Orx2 (F4, 19 =
2.109, p ≤ 0.120).
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Figure 5
Treatment results on a2A-positive cells in the BLA
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Fig 5. MK-1064 did not alter the number of cells expressing α2A. Yohimbine had a modest, yet not significant,
increase in cells expressing α2A.
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Figure 6
Treatment results on a1A-positive cells in the BLA
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Fig 6. Both yohimbine and MK-1064 cells expressing α1A, although not significantly.
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Figure 7
Treatment results on Orx2- and a2A-positive cells in the BLA
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Fig 7. Yohimbine showed an increase, though not significant, in the number of cells expressing α2A (F4, 19 = 1.772, p
≤ 0.176). MK-1064 showed no shift in number of cells expressing α2A.
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Figure 8
Treatment results on Orx2- and a1A-positive cells
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Treatment of MK-1064
significantly reduced the
number of cells expressing
both Orx2 and α1A compared
to vehicle treated controls (F4,
19 = 1.830, p ≤ 0.165). This
treatment group, however, did
not differ from cage control
mice (top). Orx2 receptors
(top left) and α1A receptors
(bottom left) of a fastescaping female, with little
colocalization. Orx2 receptors
(top right) and α1A receptors
(bottom right) of a slowescaping female, with more
colocalization.
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